Lasma LC Kid Syrup is a pediatric formulation combining Levocetirizine dihydrochloride (2.5 mg/5 ml) and Montelukast sodium (4 mg/5 ml), designed to provide effective relief from allergic conditions in children. Levocetirizine, a selective second-generation antihistamine, acts by inhibiting peripheral histamine H1-receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, nasal congestion, and itching associated with allergic rhinitis and urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, reducing airway inflammation and bronchoconstriction commonly observed in asthma and allergic rhinitis. The synergistic action of these two agents offers comprehensive management of allergic manifestations, including seasonal and perennial allergic rhinitis, chronic urticaria, and mild to moderate asthma in pediatric patients. Lasma LC Kid Syrup is well-tolerated with a favorable safety profile, minimizing sedation and other central nervous system effects often seen with first-generation antihistamines. It is recommended to be administered once daily, preferably in the evening, to optimize therapeutic outcomes. Dosage adjustments should be made based on age and clinical response under medical supervision. This combination therapy enhances patient compliance by reducing pill burden while effectively controlling allergic symptoms in children.